Results 261 to 270 of about 304,306 (307)

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate‐to‐Severe Atopic Dermatitis

open access: yesAllergy, EarlyView.
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller   +13 more
wiley   +1 more source

Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia. [PDF]

open access: yesJ Infect Dis
Williams DJ   +12 more
europepmc   +1 more source

Severe Pulmonary Blastomycosis in a Young Adult: Probable Role of E-Cigarette Use in Immunosuppression. [PDF]

open access: yesCase Rep Med
Gupta R   +6 more
europepmc   +1 more source

A multi-modal deep learning solution for precise pneumonia diagnosis: the PneumoFusion-Net model. [PDF]

open access: yesFront Physiol
Wang Y   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy